Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

February 11, 2016February 18, 2016

Regardless of IPF Diagnosis, Acute Respiratory Worsening Is an Independent Factor That Increases Morbidity, Study Suggests

In a recent study, “Patients with Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis,” published in the CHEST journal, researchers reported that acute respiratory worsening ... Read more

February 1, 2016February 3, 2016

E-cigarette Vapor Appears to Impair Immune System, Enhances Virulence of Airway Bacteria

Lung Cancer, News

Electronic or e-cigarettes impair innate immune defenses and promote the growth of bacteria in the airways, according to the results of a recent mouse study, “Electronic cigarette inhalation alters innate immunity ... Read more

January 26, 2016January 26, 2016

IPF Patients Treated with Immunosuppressants, Steroids at Higher Risk During Flares

Idiopathic Pulmonary Fibrosis, News

Patients with idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) who are treated under a protocol free of both immunosuppressants and steroids are significantly more likely to survive the flare than those given these ... Read more

January 14, 2016January 14, 2016

Sensors in Lungs Control Asthma-Induced Immune Responses

Asthma, News, Pulmonary Hypertension

Targeting a rare population of cells within the lungs may inhibit the hyperactivity of lung immune responses that underlie several diseases, including asthma. The study, “Pulmonary neuroendocrine cells function as airway ... Read more

January 7, 2016January 8, 2016

Gut Microbiome Regulates Key Immune Responses in the Lungs

COPD, News

Researchers from the Icahn School of Medicine at Mount Sinai in New York recently showed that the microbiome, a bacteria that lives in our gut, also regulates the responses of immune cells in ... Read more

January 6, 2016January 6, 2016

Sildenafil as PAH Therapy for Children in Need of Further Study

News, Pulmonary Hypertension

A group of researchers reviewed the results from two clinical trials, STARTS-I and STARTS-II, testing the use of sildenafil as a therapy for children with pulmonary arterial hypertension (PAH), and ... Read more

December 17, 2015December 17, 2015

PD-L1 Protein Expression Needs Further Assays to Become a Biomarker for NSCLC

Lung Cancer, News

Researchers found that because expression levels of PD-L1 protein vary in patients’ tumors from non–small cell lung cancer (NSCLC), additional studies are required to develop predictive biomarkers for NSCLC. The ... Read more

December 16, 2015December 16, 2015

E-Cigarette Flavorings Linked to Likely Respiratory Disease-causing Chemicals

Lung Cancer, News

Researchers found flavoring chemicals like diacetyl, previously reported to be associated with severe respiratory disease, in the juices used in e-cigarettes. The study, entitled “Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 ... Read more

December 7, 2015December 7, 2015

Inoperable CTEPH Patients At Risk of Heart Failure May be Identified by Serum Bilirubin, 6-min Walk Distance Levels

News, Pulmonary Hypertension

In a new study entitled “Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Prospective Cohort Study,” researchers found that serum total bilirubin ... Read more

November 2, 2015November 2, 2015

Results in Fruquintinib Proof-of-Concept Phase II Clinical Trial for Non-Squamous NSCLC Show Promise

Lung Cancer, News

Pharmaceutical company Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D drug subsidiary Hutchison MediPharma Limited (HMP) will receive a $10 million dollar milestone payment from its partner Eli Lilly and Company ... Read more